ADMA Biologics (ADMA|$3.6B) - 2024 Q4 & Full Year Earnings Analysis

#ADMA ADMA Biologics 2024 Q4 & Full Year Earnings: ADMA Biologics reported a 65% increase in revenue and a significant EPS beat in Q4 2024, driven by strong product sales and strategic initiatives.

- Revenue: $426.5M, 65% YoY Increase

- Adj. EPS: $0.46 vs. forecast $0.15 (1 analyst)

- Net Income FY2024: $197.7M

- High-Titer Plasma Contracts: Secured

- FDA Approval Anticipation: Mid-2025

"ADMA delivered exceptional operating and financial results in 2024, with total revenues and Adjusted EBITDA growing 65% and 309% year-over-year, respectively. These results reflect our commitment to operational and financial excellence, as well as the meaningful impact our therapies continue to have on immunocompromised patients," said Adam Grossman, President and Chief Executive Officer of ADMA.

If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover.

*Check out our latest videos on more earnings:*